Chronic low-level administration of diquat increases the nociceptive response to gastric distension in rats: role of mast cells and tachykinin receptor activation

[1]  G. Nilsson,et al.  IgE receptor‐mediated release of nerve growth factor by mast cells , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[2]  Miner,et al.  The effects of capsaicin on reflux, gastric emptying and dyspepsia , 2000, Alimentary pharmacology & therapeutics.

[3]  Theodorou,et al.  Reduction of the nociceptive response to gastric distension by nitrate ingestion in rats , 1999, Alimentary pharmacology & therapeutics.

[4]  Picard,et al.  Role of kinin B1 and B2 receptors and mast cells in post intestinal infection‐induced hypersensitivity to distension , 1998, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[5]  V. Théodorou,et al.  Low-level exposure to diquat induces a neurally mediated intestinal hypersecretion in rats: involvement of nitric oxide and mast cells. , 1998, Toxicology and applied pharmacology.

[6]  P. Anton,et al.  Neuroimmunomodulation in Inflammatory Bowel Disease: How Far from “Bench” to “Bedside”? a , 1998, Annals of the New York Academy of Sciences.

[7]  C. Maggi,et al.  MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist , 1998, British journal of pharmacology.

[8]  V. Théodorou,et al.  Involvement of interleukin‐1, prostaglandins and mast cells in rectal distension‐induced colonic water secretion in rats , 1998, The Journal of physiology.

[9]  V. Théodorou,et al.  Stress‐induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells , 1997, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[10]  P. Mclean,et al.  Effects of nematode infection on sensitivity to intestinal distension: role of tachykinin NK2 receptors. , 1997, European journal of pharmacology.

[11]  C. Maggi.  The effects of tachykinins on inflammatory and immune cells , 1997, Regulatory Peptides.

[12]  L Bueno,et al.  Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. , 1997, Gastroenterology.

[13]  S. McMahon.  NGF as a mediator of inflammatory pain. , 1996, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[14]  G. Sant,et al.  Mast cell and substance P-positive nerve involvement in a patient with both irritable bowel syndrome and interstitial cystitis. , 1996, Urology.

[15]  D. McKay,et al.  The interaction between mast cells and nerves in the gastrointestinal tract. , 1994, Immunology today.

[16]  L. Buéno,et al.  Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats. , 1994, Gastroenterology.

[17]  P. Soubrié,et al.  In vitro and in vivo biological activities of SR140333, a novel potent non-peptide tachykinin NK1 receptor antagonist. , 1993, European journal of pharmacology.

[18]  H. Kaneko,et al.  Immunoreactive-somatostatin, substance P, and calcitonin gene-related peptide concentrations of the human gastric mucosa in patients with nonulcer dyspepsia and peptic ulcer disease. , 1993, The American journal of gastroenterology.

[19]  J. Heylings,et al.  Diquat-Induced Intestinal Secretion in the Anaesthetized Rat , 1992, Human & experimental toxicology.

[20]  S. Harrison,et al.  The non‐peptide NK1 receptor antagonist, (±)‐CP‐96,345, produces antinociceptive and anti‐oedema effects in the rat , 1992, British journal of pharmacology.

[21]  C. Broomfield,et al.  Evidence of NK1 and NK2 tachykinin receptors and their involvement in histamine release in a murine mast cell line , 1992, Neuropeptides.

[22]  C. Nast,et al.  Calcitonin gene-related peptide and substance P decrease in the rabbit colon during colitis : a time study , 1991 .

[23]  J. Malagelada,et al.  The origin of symptoms on the brain-gut axis in functional dyspepsia. , 1991, Gastroenterology.

[24]  G. Sanger,et al.  The effects of granisetron, ICS 205–930 and ondansetron on the visceral pain reflex induced by duodenal distension , 1990, British journal of pharmacology.

[25]  T. Ness,et al.  Visceral pain: a review of experimental studies , 1990, Pain.

[26]  R. Stead,et al.  Mast cells are closely apposed to nerves in the human gastrointestinal mucosa. , 1989, Gastroenterology.

[27]  M. Church,et al.  Characterization of neuropeptide‐induced histamine release from human dispersed skin mast cells , 1988, British journal of pharmacology.

[28]  T. Ness,et al.  Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudaffective reflexes in the rat , 1988, Brain Research.

[29]  S. Snyder,et al.  Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Vatn,et al.  A double-blind crossover study of the effect of a chromone carboxylic acid, FPL 52694, on overnight fasting gastric acid secretion. , 1986, Scandinavian journal of gastroenterology.

[31]  T. Hökfelt,et al.  Immunoreactive calcitonin gene-related peptide and substance P coexist in sensory neurons to the spinal cord and interact in spinal behavioral responses of the rat , 1984, Neuroscience Letters.

[32]  J. Gauldie,et al.  Mucosal mast cells. I. Isolation and functional characteristics of rat intestinal mast cells. , 1982, Journal of immunology.

[33]  F. Lembeck,et al.  Analgesic effect of antagonists of substance P. , 1981, Biochemical and biophysical research communications.

[34]  E. Lock,et al.  Effects of diquat on the gastrointestinal tract of rats. , 1977, Toxicology and applied pharmacology.

[35]  U. Holzer‐Petsche,et al.  Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. , 1997, Pharmacology & therapeutics.

[36]  T. Hachet,et al.  A multifunction and programmable computerized barostat. , 1993, Gastroenterologie clinique et biologique.